Harrow (HROW) Q1 2026: VEVY Net Pricing Reset Lifts Outlook as Demand Surges 25%
Harrow’s Q1 revealed a one-off $8 million revenue hit from VEVY’s gross-to-net miscalculation, but underlying demand and market share gains remain robust. The company’s decisive business rule changes have already restored net pricing, with no impact to prescription momentum. With expanded sales forces now fully deployed and multiple product catalysts on deck, Harrow is positioned for accelerating growth and improved profitability into the back half of 2026 and beyond.
Summary
- VEVY Pricing Correction: Gross-to-net issue resolved without denting demand or prescriber growth.
- Sales Force Expansion: Doubling of commercial teams now translating into higher prescription highs and market share gains.
- Second Half Catalysts: New launches and improved reimbursement set up a stronger back half with multiple high-margin growth drivers.
Business Overview
Harrow is a specialty pharmaceutical company focused on ophthalmology, generating revenue through branded prescription drugs, compounded formulations, and cash-pay products. Its core segments include VEVY (dry eye), IHESO (retina/in-office procedures), TriEssence (ocular inflammation), and Access Plus (cash pay). The company’s model leverages a broad portfolio of FDA-approved and compounded drugs, a scaled commercial infrastructure, and targeted investments in sales force expansion and product launches to drive share in large, underpenetrated markets.
Performance Analysis
Q1 revenue was pressured by an $8 million one-time gross-to-net adjustment tied to VEVY’s new commercial coverage, as a surge in high deductible patient volume outpaced financial modeling. Management moved quickly to cap copay buy-downs and refine business rules, restoring net pricing for Q2 onward. Notably, prescription demand for VEVY soared—new prescriptions up 25% sequentially and total prescriptions up 11%— even as the overall branded dry eye market declined 18% in the quarter.
IHESO demand continued to build, with 18% unit growth YoY and a 21% increase in new ordering accounts, though revenue remained muted by channel inventory and packaging transition. TriEssence delivered its sixth consecutive quarter of unit volume growth, up 136% YoY, with expanding adoption in ocular surgery. The Access Plus cash pay business rebounded as inventory constraints were resolved, and the company is now increasing safety stock and sales coverage.
- VEVY Market Share Acceleration: VEVY surpassed Zydra in total prescriptions and now holds a 14% branded share, achieved with half the current sales force.
- IHESO Channel Dynamics: Revenue remains below prior year but is set to rebound with multi-unit packaging and improved pricing in Q3.
- TriEssence Expansion: 250% unit growth over six quarters, with new account growth and label expansion studies underway.
Despite Q1’s headline revenue dip, underlying demand signals, sales force leverage, and operational execution point to a strong setup for sequential growth and margin improvement through 2026.
Executive Commentary
"Our data demonstrates that demand for our key growth drivers is accelerating. Further, our market share capture is sustainable and will translate into profitable revenue growth."
Mark L. Baum, Chief Executive Officer
"We acted immediately, implementing targeted business rule changes, including strict caps on copay buy downs and other program refinements to protect our net pricing going forward. These program changes have isolated this to be primarily a first quarter issue and we are now well positioned to receive the complete economic benefit we expect from our expanded coverage moving forward, beginning in Q2."
Andrew Bull, President and Chief Financial Officer
Strategic Positioning
1. VEVY Demand Engine and Commercial Coverage
VEVY, dry eye therapy, is now the fastest-growing branded product in its category, with prescription growth outpacing declining market trends. The gross-to-net correction, while a short-term revenue drag, has not impaired demand or prescriber adoption. Full commercial coverage and new business rules position VEVY for improved net revenue per prescription and further share gains as the expanded sales force matures.
2. Sales Force Scale and Execution
Harrow doubled its VEVY sales team and tripled TriEssence sales coverage, recruiting experienced ophthalmic reps. Early Q2 data shows higher daily prescription highs and broader account penetration, with management emphasizing that the “engine is now in place” to convert demand into revenue and profitability.
3. Pipeline and Product Launch Catalysts
Multiple near-term catalysts underpin the second half: BioViz and Biclovi launches, IHESO’s permanent J-code reimbursement, multi-unit packaging, and retina-specific clinical data. These are expected to drive incremental, high-margin revenue and broaden Harrow’s portfolio reach.
4. Margin and Pricing Leverage
Net pricing for VEVY is expected to improve by roughly 30% in Q2 versus Q1, with similar tailwinds anticipated for IHESO as new packaging and reimbursement dynamics take effect. Management is focused on sustaining margin expansion through disciplined commercial mix and payer coverage wins.
5. Durable Demand and Market Expansion
Management points to “durable, sustainable reimbursement” and near-pervasive coverage, especially for in-office procedures, as key to replacing ASC volume and supporting long-term revenue growth. Portfolio breadth and refill rates provide further insulation against competitive or macro shocks.
Key Considerations
Harrow’s Q1 was defined by operational agility—rapidly identifying and correcting a major pricing issue while maintaining demand momentum. The commercial organization’s scale-up, combined with robust product demand and multiple pipeline launches, sets the stage for an inflection in both top-line and margin performance.
Key Considerations:
- Gross-to-Net Reset: The $8 million Q1 revenue impact is isolated, with business rule changes already restoring net pricing and protecting future profitability.
- Sales Force Productivity: New hires are experienced, already driving higher prescription volumes and account breadth, with more impact expected in Q2 and beyond.
- Pipeline Visibility: Upcoming launches (BioViz, Biclovi) and new reimbursement codes offer incremental, high-margin growth drivers not yet fully reflected in current run rates.
- Portfolio Diversification: Expansion into ocular inflammation, in-office retina, and cash pay segments reduces reliance on any single product and broadens addressable market.
Risks
Execution risk remains around rapid sales force expansion and new product launches, especially as many reps are newly in the field and pipeline assets are early in commercialization. Reimbursement shifts and payer mix volatility could pressure net pricing, while competitive responses in dry eye and retina markets may slow share gains. Management’s ability to translate demand into sustained revenue and margin improvement will be closely scrutinized across the next two quarters.
Forward Outlook
For Q2 2026, Harrow guided to:
- Total revenues of $71 to $81 million
- Sequential growth in VEVY and initial BioViz revenue recognition
For full-year 2026, management reaffirmed guidance:
- Total revenue of $350 million to $365 million
Management highlighted:
- Restored VEVY net pricing and accelerating demand trends
- Second half catalysts including product launches, reimbursement milestones, and clinical data readouts
Takeaways
- VEVY’s demand and market share gains are robust, with pricing and coverage now reset for improved profitability in Q2 and beyond.
- Sales force expansion and pipeline launches underpin a strong second half, with multiple incremental growth levers across the portfolio.
- Investors should watch for margin expansion, execution on new launches, and evidence of sustained demand conversion as key value drivers through 2026.
Conclusion
Harrow’s Q1 headline revenue miss masks a business in accelerating transition, with demand fundamentals, sales force leverage, and pipeline execution setting up a multi-quarter growth inflection. Management’s operational agility and clear visibility into catalysts position the company for sustained revenue and margin expansion.
Industry Read-Through
Harrow’s experience with gross-to-net volatility and rapid commercial scale-up offers a playbook for specialty pharma peers navigating payer mix shifts and high-deductible seasonality. The company’s ability to drive share in a declining branded market, leverage new reimbursement codes, and launch pipeline assets with expanded sales teams signals an era where commercial agility and portfolio breadth are critical to navigating reimbursement headwinds and competitive intensity. Other ophthalmic and specialty drug makers should heed Harrow’s approach to payer engagement, sales force investment, and multi-pronged growth strategies as key levers for durable outperformance in dynamic markets.